Regeneron's BLA for fusion protein
March 9th 2011We may know within 6 to 10 months the results of the FDA?s review of Regeneron Pharmaceuticals? biologics license application (BLA) related to a fusion protein (VEGF Trap-Eye) for the treatment of neovascular age-related macular degeneration (AMD). If the review is favorable, use of the fusion protein ultimately could mean fewer injections per year for patients being treated for the disease.